Close this search box.
    • Small Molecules
      • Discovery
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers
Close this search box.


CAR T-cell therapies combine cellular therapy, gene therapy and immune therapy to use a patient’s own T-cells to fight cancers. It is this potential for harnessing our immune systems to fight cancer that makes CAR T-cell therapies so revolutionary and earns them the name, “living drugs”.

Syngene is contributing to this revolutionary field by helping our clients evaluate their novel medicines/molecules for their mode of action, in vivo functional efficacy and other vital characteristics.  Our end-to-end in vitro and in vivo immuno-oncology assessment platform allows fast and accurate validation of treatment approaches.

Our capabilities in supporting CAR-T cell research

  • Design of CAR constructs
  • CRISP-R gene editing
  • Primary T-cell assays
    • Human PBMCs isolation, sorting
    • Cytotox assay with co-cultured cancer cells
    • Proliferation
    • Cytokine profile
  • Virus generation for CAR delivery
    • Lentivirus packaging
    • Transduction efficiency
  • Efficacy studies in syngeneic models
  • Ex-vivo immuno-phenotyping of TILs
  • PDX and humanized mouse models
  • Preclinical evaluation
    • In vivo proliferation of effector cells: CAR expression and CFSE assay
    • Xenograft tumor growth inhibition (NOG-SCID mice)
    • Survival as endpoint
    • Whole animal imaging — Biodistribution
  • Biorepositories
    • Collaboration with multiple local and national medical centers for healthy and patients’ samples (blood, tissues)
    • Currently banking >200 healthy donor PBMC ready to use

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details